Edition:
United States

STRATA Skin Sciences Inc (SSKN.OQ)

SSKN.OQ on NASDAQ Stock Exchange Capital Market

1.29USD
2:54pm EST
Change (% chg)

$0.07 (+5.74%)
Prev Close
$1.22
Open
$1.28
Day's High
$1.39
Day's Low
$1.25
Volume
40,644
Avg. Vol
43,400
52-wk High
$5.40
52-wk Low
$1.06

Latest Key Developments (Source: Significant Developments)

Strata Skin Sciences Announces Exploration Of Strategic Alternatives
7:00am EST 

Dec 18 (Reuters) - Strata Skin Sciences Inc ::STRATA SKIN SCIENCES ANNOUNCES EXPLORATION OF STRATEGIC ALTERNATIVES.STRATA SKIN SCIENCES INC - BOARD HAS ENTERED A PROCESS TO EXPLORE AND REVIEW STRATEGIC ALTERNATIVES.STRATA SKIN SCIENCES INC - REVIEW OF STRATEGIC ALTERNATIVES MAY INCLUDE A SALE OF COMPANY OR OTHER TRANSACTION.STRATA SKIN SCIENCES INC - ‍ COMPANY IS IN THE PROCESS OF ENGAGING A FINANCIAL ADVISER​.  Full Article

Strata Skin Sciences Announces Departure Of Chief Financial Officer
Wednesday, 6 Dec 2017 04:01pm EST 

Dec 6 (Reuters) - Strata Skin Sciences Inc ::STRATA SKIN SCIENCES ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.STRATA SKIN SCIENCES INC - CHRISTINA ALLGEIER RESIGNED AS CHIEF FINANCIAL OFFICER.STRATA SKIN SCIENCES INC - ALLGEIER INTENDS TO REMAIN IN HER CURRENT ROLE THROUGH DECEMBER 31.  Full Article

Strata Skin Sciences reports Q3 loss of $5.52 per share
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Strata Skin Sciences Inc :Strata skin sciences reports third quarter 2017 financial results.Q3 loss per share $5.52.Q3 revenue $7.5 million versus $7.8 million.Strata skin sciences - ‍as of Sept 30, 2017, co had cash & cash equivalents of $3.1 million.  Full Article

Leviticus Partners reports 9.69 pct passive stake in Strata Skin Sciences
Thursday, 2 Nov 2017 02:54pm EDT 

Nov 2 (Reuters) - Leviticus Partners L.P.::Says reports 9.69 pct passive stake in Strata Skin Sciences Inc as of Oct 24, 2017 - SEC filing‍​.  Full Article

Strata Skin Sciences receives FDA response letter on Sept 5 for possible clearance of dosing technology
Wednesday, 6 Sep 2017 01:06pm EDT 

Sept 6 (Reuters) - Strata Skin Sciences Inc ::Says ‍on Sept 5 received response letter from U.S. FDA concerning possible paths for 510k clearance of new optimal dosing technology​.Says FDA response letter proposes two alternative paths for seeking regulatory clearance - SEC filing.Says ‍first path for seeking regulatory clearance requires a clinical trial to substantiate potential claims for OTD​.Says ‍second path for seeking regulatory clearance is to seek regulatory clearance with no new claims regarding treatment/ efficacy​.Says company is assessing alternatives for proceeding and is considering related costs and availability of cash resources​.Says ability to finance path/combination,other product development through conversion of outstanding convertible debentures due in 2021.  Full Article

STRATA Skin Sciences Q2 loss per share $0.52
Thursday, 10 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - STRATA Skin Sciences Inc :STRATA Skin Sciences reports second quarter 2017 financial results.Q2 loss per share $0.52.Q2 revenue $8.7 million versus $7.7 million.  Full Article

Strata Skin Sciences to eliminate $40.7 mln outstanding senior secured convertible debentures
Wednesday, 7 Jun 2017 08:00am EDT 

June 7 (Reuters) - Strata Skin Sciences Inc :Strata Skin Sciences announces agreement to eliminate $40.7 million of outstanding senior secured convertible debentures.Strata Skin Sciences-holders of 2.25% senior series A secured convertible debentures, 4% senior secured convertible debentures due July 30, 2021 to exchange it.Strata Skin Sciences Inc - Holders of specific debentures to exchange them into 40,617 shares of newly created series C convertible preferred stock.Strata Skin Sciences Inc - Exchange to also eliminate Strata's obligation to pay approximately $4 million of cash interest payments over next four years.Strata Skin Sciences Inc - Upon completion of exchange, aggregate principal amount of Strata's debt will be reduced to approximately $12 million.  Full Article

Strata Skin Sciences Q1 loss per share $1.03
Thursday, 11 May 2017 04:01pm EDT 

May 11 (Reuters) - Strata Skin Sciences Inc ::Strata skin sciences reports first quarter 2017 financial results.Q1 loss per share $1.03.Q1 revenue $7.3 million versus $7.6 million.Strata skin sciences inc says q1 recurring xtrac revenues were $5.7 million, up 3.7% year-over-year.Strata skin sciences inc says q1 installed base of xtrac systems in u.s. Expands to 791 systems placed, up 8.4% from 730 at end of q1 2016.  Full Article

STRATA Skin Sciences says announces launch of the Nordlys system
Thursday, 27 Apr 2017 08:01am EDT 

April 27 (Reuters) - Strata Skin Sciences Inc :Strata skin sciences, inc. Announces launch of the nordlys system and announces 2017 revenue expectations for nordlys hybrid system.Forecasting sales of nordlys products to be in range of $4.0 to $4.5 million for 2017.  Full Article

Strata Skin Sciences, Inc. Announces 1-for-5 reverse stock split
Thursday, 6 Apr 2017 10:30am EDT 

Strata Skin Sciences Inc : Strata Skin Sciences, Inc. Announces 1-for-5 reverse stock split .Strata Skin Sciences - reverse stock split of shares of common stock at ratio of 1-for-5 to become effective 5:00 p.m. Eastern time on April 6, 2017.  Full Article